Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Bright Peak synthesizing proteins like they’re small molecules with $35M from Versant

Bright Peak brings a chemical synthesis approach to the modified IL-2 arena

Bright Peak thinks its medicinal chemistry approach to protein design will make its synthetic cytokines stand out from the pack.

Built by Versant Ventures’ Basel-based Ridgeline outpost with technology licensed from ETH Zurich, Bright Peak Therapeutics Inc. emerged from two years of stealth Tuesday with a $35 million series A round and a pipeline of synthetic cytokine therapies for cancer. The company’s lead candidate, a modified version of IL-2, is in IND-enabling studies and is slated to enter the clinic in 2H21.

At least three other companies are using protein modification technologies to make versions of IL-2 that

Read the full 979 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE